Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Gains from Investment Securities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Gains from Investment Securities for 15 consecutive years, with $37000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 270.0% to $37000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4000.0, a 121.05% decrease, with the full-year FY2025 number at -$4000.0, down 121.05% from a year prior.
  • Gains from Investment Securities was $37000.0 for Q4 2025 at Niagen Bioscience, up from -$15000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $84000.0 in Q3 2021 to a low of -$135000.0 in Q4 2021.
  • A 5-year average of -$4473.7 and a median of $4000.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 270.0% in 2025; the steepest drop was 680.0% in 2025.
  • Niagen Bioscience's Gains from Investment Securities stood at -$135000.0 in 2021, then skyrocketed by 134.81% to $47000.0 in 2022, then skyrocketed by 59.57% to $75000.0 in 2023, then crashed by 86.67% to $10000.0 in 2024, then surged by 270.0% to $37000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Gains from Investment Securities are $37000.0 (Q4 2025), -$15000.0 (Q3 2025), and -$29000.0 (Q2 2025).